On Tuesday, Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was -5.36% drop from the session before settling in for the closing price of $8.39. A 52-week range for CRVS has been $2.54 – $9.60.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 8.47%. When this article was written, the company’s average yearly earnings per share was at 58.29%. With a float of $57.33 million, this company’s outstanding shares have now reached $74.68 million.
Corvus Pharmaceuticals Inc (CRVS) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Corvus Pharmaceuticals Inc stocks. The insider ownership of Corvus Pharmaceuticals Inc is 23.24%, while institutional ownership is 37.72%. The most recent insider transaction that took place on Jun 27 ’25, was worth 4,891,894. In this transaction Director of this company sold 1,176,332 shares at a rate of $4.16, taking the stock ownership to the 7,165,006 shares. Before that another transaction happened on Jun 27 ’25, when Company’s Director sold 1,176,332 for $4.16, making the entire transaction worth $4,891,894. This insider now owns 7,165,006 shares in total.
Corvus Pharmaceuticals Inc (CRVS) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -0.14 earnings per share (EPS) during the time that was less than consensus figure (set at -0.12) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 58.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.36% during the next five years compared to 8.47% growth over the previous five years of trading.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Trading Performance Indicators
You can see what Corvus Pharmaceuticals Inc (CRVS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 8.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.53, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.55 in one year’s time.
Technical Analysis of Corvus Pharmaceuticals Inc (CRVS)
Compared to the last year’s volume of 0.87 million, its volume of 1.82 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 15.88%.
During the past 100 days, Corvus Pharmaceuticals Inc’s (CRVS) raw stochastic average was set at 70.57%, which indicates a significant increase from 4.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.56 in the past 14 days, which was higher than the 0.44 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.01, while its 200-day Moving Average is $5.33. Nevertheless, the first resistance level for the watch stands at $8.32 in the near term. At $8.70, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.93. If the price goes on to break the first support level at $7.71, it is likely to go to the next support level at $7.49. Now, if the price goes above the second support level, the third support stands at $7.11.
Corvus Pharmaceuticals Inc (NASDAQ: CRVS) Key Stats
There are 74,682K outstanding shares of the company, which has a market capitalization of 592.97 million. As of now, sales total 0 K while income totals -62,290 K. Its latest quarter income was 0 K while its last quarter net income were -10,160 K.
